IQANOVA
AI-driven quantitative systems pharmacology (AI-QSP) platform for drug development.
Website: http://www.iqanova.org/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | IQANOVA |
| Tagline | AI-driven quantitative systems pharmacology (AI-QSP) platform for drug development |
| Headquarters | Edinburgh, United Kingdom [GOV.UK] |
| Founded | 2025 [GOV.UK] |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
Links
Publicly reported
- Website: http://www.iqanova.org/
Summary and Signal
PUBLIC IQANOVA is an Edinburgh startup building an AI-driven quantitative systems pharmacology platform for drug development, and it merits attention now because the public record shows a newly incorporated company trying to compress one of biopharma R&D's slower workflows, mechanistic model building and simulation, into a more automated software layer [GOV.UK] [IQANOVA, July 2026]. Companies House records indicate IQANOVA LTD was incorporated in Scotland on 20 January 2025, later changing its name from MMWR BRAIN LTD on 5 September 2025, which places the business at a very early formation stage even by pre-seed standards [GOV.UK].
The product thesis is clear in the company's own materials: IQANOVA says it combines QSP, PBPK, and PBBM mechanistic models with AI surrogates, living SBML models, genome-scale metabolic models, and regulatory-oriented documentation for model-informed drug development [IQANOVA, July 2026]. That positioning is at least directionally differentiated from a pure AI tooling pitch because it anchors the software in established pharmacology and systems-biology workflows, although the evidence available today remains almost entirely company-originated and conference-adjacent rather than customer-validated [IQANOVA, April 2026] [InSysBio, 2026].
The main gap in the file is the team. Publicly available sources support a 2025 founding date and a 1 to 10 employee footprint, but they do not identify named founders or provide verifiable biographies, so any view on scientific credibility or commercial execution still rests more on the technical ambition of the product than on observable operator track records [GOV.UK] [IQANOVA, July 2026].
On capitalization and go-to-market, the evidence is similarly thin. No verifiable funding round, investor, round size, customer deployment, or pharma partnership was identified in the available sources, while the company's website instead points to a founding partner programme for model co-development and confidential briefings, which is consistent with a B2B pre-revenue commercial motion but does not yet establish repeatable demand [IQANOVA, July 2026].
Over the next 12 to 18 months, the practical markers to watch are straightforward: named scientific leadership, disclosed pilots or pharmaceutical collaborators, evidence that the founding partner programme converts into paid work, and any independent validation that the platform reduces model-development time without compromising regulatory utility [IQANOVA, July 2026] [GOV.UK]. For now, the public record supports interest in the category fit and technical ambition, but not a firm view on commercial traction.
No independent source found -- This section relies materially on company website claims and Companies House records, with limited independent corroboration beyond a conference listing.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
Company Overview
PUBLIC
The cleanest way to frame IQANOVA is as a newly formed Edinburgh drug-development software company whose public record is still mostly corporate and self-described, rather than market-validated. Companies House records show IQANOVA LTD is an active private limited company registered in Scotland under company number SC834762, incorporated on 20 January 2025, with a registered office at 13-15 Morningside Drive, Edinburgh, EH10 5LZ and SIC code 72190 for other research and experimental development on natural sciences and engineering [GOV.UK]. The same filing record shows the company was originally incorporated as MMWR BRAIN LTD and changed its name to IQANOVA on 5 September 2025 [GOV.UK].
From there, the visible milestones are limited but directionally consistent. The company website describes IQANOVA as an AI-driven quantitative systems pharmacology platform for drug development, combining mechanistic approaches such as QSP, PBPK, and PBBM with AI surrogates and regulatory documentation workflows [IQANOVA, July 2026]. Public conference activity appears to predate the formal company launch: a QSPC 2022 conference page attributes a presentation on integrating genome-scale metabolism and quantitative immune databases for AI-driven QSP modeling to the team behind the work, using an asthma case study [InSysBio, 2026]. By April 2026, IQANOVA was publicly describing an AI-QSP initiative and conference presentations around automated model generation, surrogate validation, and genome-scale metabolic modeling, which suggests the company had moved from technical thesis to outward-facing product positioning within roughly its first year of incorporation [IQANOVA, April 2026].
What remains absent matters almost as much as what is present. State filings establish the legal entity and timeline, and the website establishes the product thesis, but the public record does not yet identify founders, investors, or commercial counterparties through the permitted source set for this section [GOV.UK] [IQANOVA, July 2026]. That leaves IQANOVA, at least on public evidence, as an early-stage computational biology venture with a defined technical narrative and a verified corporate footprint, but an incomplete operating profile.
No independent source found -- This section relies on state filings plus company-controlled website materials, with one conference page for technical activity but no independent public reporting on operations, financing, or founders.
The Product and the Stack
MIXED
The product claim here is conceptually clear even if the public evidence is still thin. IQANOVA describes an AI-driven quantitative systems pharmacology platform for drug development that combines mechanistic modeling with machine-learning surrogates, with the stated aim of reducing the time and computational burden involved in model-informed drug development decisions [IQANOVA, July 2026]. On the company website, that stack is described as spanning QSP, PBPK, and PBBM models, alongside living SBML models, genome-scale metabolic models, and regulatory-ready documentation [IQANOVA, July 2026].
The company also frames the platform around a fairly specific workflow rather than a general AI claim. Public materials cite scalable QSP model generation and simulation, rapid surrogate modeling, metabolic and immune-system integration, virtual-population generation, precision medicine applications, and broader computational drug development support [IQANOVA, July 2026]. A July 2026 website page also references a founding partner programme for co-developing models, requesting access to genome-scale metabolic-model resources, integrating ATLAS, or arranging a confidential briefing, which suggests the current commercial surface may still be collaborative and services-adjacent rather than a fully standardized software product [IQANOVA, July 2026].
The most concrete third-party signal is conference activity, not deployment evidence. InSysBio's archived QSPC 2022 materials describe work on integrating genome-scale metabolism and quantitative immune databases for AI-driven QSP modeling, using an asthma case study with EHMN 2026, which is directionally consistent with the company's later product positioning [InSysBio, 2026]. Separately, company-originated materials say IQANOVA launched an AI-QSP initiative and presented at QSPC 2026 on AI-QSP, genome-scale metabolic modeling, surrogate validation, and automated model generation, but those claims remain company-sourced and do not establish customer usage, validated performance, or regulatory adoption [IQANOVA, July 2026].
No independent source found -- Material product details rely primarily on company website claims, with limited external corroboration from a conference archive.
The Market They Are Entering
PUBLIC
This market matters now because the commercial case for AI-assisted drug-development software rises or falls on whether pharma is willing to buy faster modeling workflows before they are fully standardized across discovery, translational, and regulatory teams, and the public record here is still much clearer on the technical thesis than on measured market demand for IQANOVA specifically [IQANOVA, July 2026].
The first constraint is simple: there is no cited third-party TAM, SAM, or SOM in the available source set for AI-QSP, model-informed drug development, or adjacent software categories tied directly to IQANOVA. Public materials position the company around quantitative systems pharmacology, PBPK, PBBM, AI surrogates, and regulatory-ready documentation for drug-development decisions [IQANOVA, July 2026]. That places the company at the intersection of computational drug-development software, pharmacometrics tooling, and outsourced or software-enabled modeling services, but any hard market-sizing claim beyond that would be inference rather than reporting.
Demand drivers are easier to describe than market size because they follow directly from the product positioning. IQANOVA says it aims to reduce the computational burden and time involved in building, simulating, and documenting models used in drug-development decisions, and it frames use cases around scalable QSP generation, surrogate modeling, metabolic and immune-system integration, virtual populations, and precision medicine [IQANOVA, July 2026]. If those needs are real inside sponsor organizations, the budget holder is likely not a single buyer but a mix of pharmacometrics, translational science, clinical strategy, and regulatory teams, which fits the company's own description of target stakeholders in pharma R&D and related functions [IQANOVA, July 2026].
Adjacent and substitute markets are also visible from the technical stack. A buyer evaluating this kind of platform could route spend toward established PBPK or pharmacometrics software, internal modeling teams, academic collaborations, contract research partners, or narrower AI tools that speed simulation without owning the full mechanistic workflow. That matters because IQANOVA's public wedge is not simply "AI for biotech" in general terms, but a more specific attempt to combine mechanistic models with AI surrogates and biological-data integration in a form that could support both scientific and regulatory work [IQANOVA, July 2026].
Regulatory and macro forces cut both ways. On the positive side, the company's emphasis on living SBML models and regulatory-ready documentation suggests it is aiming at a part of the market where auditability and model traceability matter, which is a more durable position than a pure black-box prediction product if customers and regulators want explainable workflows [IQANOVA, July 2026]. On the limiting side, the public evidence does not yet show named commercial customers, pharmaceutical collaborations, or third-party validation in major industry coverage, so the current market read is about category plausibility rather than demonstrated budget capture [InSysBio, 2026].
| Market lens | Public evidence | Source |
|---|---|---|
| Core category | AI-driven quantitative systems pharmacology platform for drug development | [IQANOVA, July 2026] |
| Adjacent categories | PBPK, PBBM, genome-scale metabolic modeling, model-informed drug development | [IQANOVA, July 2026] |
| Demand signal cited publicly | Company positions the product around reducing time and computational burden in model building and simulation | [IQANOVA, July 2026] |
| Market validation gap | No named customer, paid deployment, or announced pharma collaboration identified in available sources | [InSysBio, 2026] |
The table points to a market that is conceptually legible but still thinly evidenced in public. The category logic is coherent, yet the available record does not support a quantified claim about current market share, segment size, or near-term adoption velocity.
No independent source found -- This section relies primarily on company materials for category definition and use-case framing, with only limited third-party corroboration from a conference listing and no named third-party market-sizing source.
The Competitive Field
MIXED The company is positioning itself against a broad set of established model-informed drug development workflows, but the public record does not yet support a clean head-to-head map against named startup rivals [IQANOVA, July 2026] [GOV.UK].
The first competitive segment is incumbent scientific software and services, not venture-backed AI peers. IQANOVA's public materials place it in quantitative systems pharmacology, PBPK, and PBBM workflows for drug development, with an added layer of AI surrogates and regulatory documentation [IQANOVA, July 2026]. In practice, that means its closest alternatives may be existing in-house pharmacometrics teams, contract research relationships, and established modeling toolchains already used by biopharma teams, rather than a clearly disclosed set of direct startup competitors. The company's own evidence base points to conference activity and product positioning, but not yet to named commercial displacements, customer migrations, or published benchmarks against other vendors [InSysBio, 2026] [IQANOVA, April 2026].
A second segment is adjacent substitute workflows built around manual model construction and conventional computational biology stacks. IQANOVA argues that its edge is the combination of mechanistic QSP, PBPK, and PBBM models with AI surrogates, living SBML models, genome-scale metabolic models, and regulatory-ready documentation, all inside one platform narrative [IQANOVA, July 2026]. That is potentially differentiated at the product-design level, because many teams still assemble these capabilities through separate software, internal scripts, and specialist consultants. The constraint is durability: this edge is still company-described, and the public record does not show named distribution partners, proprietary datasets, regulatory endorsements, or customer references that would make the advantage hard for better-capitalized incumbents to absorb or replicate [IQANOVA, July 2026] [GOV.UK].
The present exposure is less about one disclosed rival and more about go-to-market proof. No verifiable funding round, investor, named founder biography, commercial customer, paid deployment, or announced pharmaceutical collaboration was identified in the available sources, which leaves IQANOVA competing from a relatively thin public signal base while larger software, services, and internal biopharma teams can sell from installed trust and operating history [GOV.UK] [IQANOVA, July 2026]. The absence of named competitors in the source set is itself informative here: it suggests the company has not yet framed the market publicly in the way a later-stage category builder usually would, and investors should treat differentiation claims as a thesis rather than a market-proven position [IQANOVA, July 2026].
The most plausible 18-month competitive scenario is one where incumbent workflows remain the default winner if buyers continue to prefer validated, already-integrated modeling processes over a newer AI-QSP stack. In that case, the likely loser is not a named startup rival but IQANOVA's founding-partner motion, if it fails to convert conference visibility and technical breadth into referenceable collaborations [IQANOVA, April 2026] [IQANOVA, July 2026]. The upside case is narrower and still credible: IQANOVA can win if a small number of research partners value faster surrogate-based model generation and are willing to co-develop around metabolic and immune-system integration before broader procurement standards harden [InSysBio, 2026] [IQANOVA, July 2026].
One source, partially checked -- Based primarily on company materials and Companies House records, with partial corroboration from conference evidence; no independently verified named competitors or customer-displacement data were identified.
Opportunity
Upside Case
PUBLIC The prize here is unusually large if the company can turn a credible scientific workflow into repeatable software adoption: model-informed drug development sits close to expensive decisions in preclinical and clinical programs, so even a narrow software footprint can matter if it becomes a trusted part of how teams build, simulate, and document mechanistic models for development and regulatory work [IQANOVA, July 2026] [GOV.UK].
The headline opportunity is not that IQANOVA becomes a broad AI drug-discovery company. The public record supports a narrower and, in some ways, cleaner possibility: a specialist platform for AI-assisted quantitative systems pharmacology and adjacent model-informed drug development workflows, aimed at reducing the time and computational burden involved in building, simulating, and documenting models used in development decisions [IQANOVA, July 2026]. That is still an ambitious target, but it is at least directionally reachable from the evidence in hand because the company has put a specific product thesis in public, tied it to concrete model types such as QSP, PBPK, and PBBM, and shown category participation through conference presentations on AI-QSP, genome-scale metabolic modeling, surrogate validation, and automated model generation [IQANOVA, April 2026] [InSysBio, 2026].
The near-term paths to scale are easier to frame as scenarios than as a single deterministic arc, because there is no public evidence yet of customers, financing, or distribution partners [GOV.UK] [IQANOVA, July 2026]. The table below stays inside what the sources support.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Founding-partner wedge | IQANOVA converts its founding partner programme into a small set of deep collaborations with pharma, biotech, or academic groups, then turns those bespoke projects into repeatable software modules and documentation workflows. | Signed co-development relationships through the founding partner programme [IQANOVA, July 2026]. | The website explicitly invites organizations to co-develop models, request access to genome-scale metabolic-model resources, integrate ATLAS, or arrange confidential briefings, which is a credible wedge for an early scientific software company before broad self-serve adoption exists [IQANOVA, July 2026]. |
| Conference-to-platform credibility | The company uses technical visibility in the QSP community to become a recognized toolchain for teams working at the intersection of mechanistic modeling and AI surrogates. | Continued publication and conference presence following the QSPC presentations [IQANOVA, April 2026] [InSysBio, 2026]. | Public materials already show category-specific technical positioning rather than generic AI claims, and the QSPC-related presentation history suggests the company is speaking to an audience that already uses these methods [InSysBio, 2026] [IQANOVA, April 2026]. |
| Regulatory-workflow layer | IQANOVA wins adoption not as the primary scientific system of record, but as the software layer that accelerates simulation and produces regulatory-ready model documentation. | Validation that teams can move from model generation to documentation with less manual work [IQANOVA, July 2026]. | The website's emphasis on living SBML models and regulatory-ready documentation points to a workflow pain point that can carry budget authority even when the underlying science stack is fragmented across teams and vendors [IQANOVA, July 2026]. |
What compounding would look like is fairly clear in theory, even if there is no public proof yet that it has started. Each successful co-development project could improve reusable model components, surrogate-model workflows, and documentation templates; those, in turn, could reduce the effort required for the next program, making the product more useful to the next buyer [IQANOVA, July 2026]. If that loop works, IQANOVA would not need massive horizontal adoption at first. It would need a handful of technically demanding users who create pressure for standardization around the company's AI-QSP workflow.
There is also a subtler compounding mechanism in the product framing. By combining mechanistic models with AI surrogates and biological data integration, IQANOVA is positioning itself between scientific depth and operational speed, which is where many applied platforms gain staying power if they can show that faster simulation does not degrade trust [IQANOVA, July 2026]. The public conference topics on surrogate validation and automated model generation matter here because they point to exactly the two objections sophisticated users tend to raise first, namely whether the models are reliable and whether the workflow is actually faster in practice [IQANOVA, April 2026].
The size of the win is harder to quantify than the product ambition, because no market-sizing source or close public comparable was provided in the source set. The cleanest public framing is therefore conditional: if IQANOVA were to become a recognized infrastructure layer for AI-assisted QSP and model-informed drug development across pharma R&D and regulatory teams, the outcome could be venture-scale because the software would sit in a high-value, low-volume part of the drug-development stack where credibility and reuse matter more than mass-market seat count [IQANOVA, July 2026]. That is a scenario, not a forecast. At this stage, the upside rests less on present traction than on whether the company can convert an unusually specific scientific thesis into repeat usage with named external organizations.
No independent source found -- This section relies primarily on company materials, Companies House records, and a conference listing; no public customer, funding, or independent commercial validation was identified [IQANOVA, July 2026] [GOV.UK] [InSysBio, 2026].
Sources
Publicly reported
[GOV.UK] IQANOVA LTD overview - Find and update company information - GOV.UK | https://find-and-update.company-information.service.gov.uk/company/SC834762
[IQANOVA, July 2026] AI-MIDD: Transforming Drug Developemnt | IQANOVA | http://www.iqanova.org/
[IQANOVA, April 2026] IQANOVA Launches AI-QSP System for Next-Gen Drug Development | https://www.linkedin.com/
[InSysBio, 2026] QSPC 2022, Leiden, The Netherlands | https://insysbio.com/our-expertise/posters/qspc-leiden-the-netherlands/
Articles about IQANOVA
- IQANOVA's AI-QSP Platform Aims to Cut Years from Drug Development Timelines — The Edinburgh startup is pitching a mechanistic modeling platform to pharmaceutical R&D teams, but its commercial traction remains unproven.